Evidence map›Paper›PMID 34374088›Full record

ArticleJournal of surgical oncology2021

A novel preoperative risk score to guide patient selection for resection of soft tissue sarcoma lung metastases: An analysis from the United States Sarcoma Collaborative.

Rachel M Lee, Cecilia G Ethun, Adriana C Gamboa, Michael K Turgeon, Thuy Tran, George Poultsides, Valerie Grignol, Meena Bedi, Harveshp Mogal, Callisia N Clarke and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Rachel M LeeDepartment of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0003-2704-839X
Cecilia G EthunDepartment of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Adriana C GamboaDepartment of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0002-5464-2178
Michael K TurgeonDepartment of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Thuy TranDepartment of Surgery, Stanford University Medical Center, Palo Alto, California, USA.
George PoultsidesDepartment of Surgery, Stanford University Medical Center, Palo Alto, California, USA.
Valerie GrignolDepartment of Surgery, Division of Surgical Oncology, The Ohio State University, Columbus, Ohio, USA.
Meena BediDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Harveshp MogalDepartment of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID http://orcid.org/0000-0001-5743-1424
Callisia N ClarkeDepartment of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Jennifer TsengDepartment of Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.ORCID http://orcid.org/0000-0002-9124-8153
Kevin K RogginDepartment of Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.
Konstantinos ChouliarasDepartment of Surgery, Wake Forest University, Winston-Salem, North Carolina, USA.
Konstantinos VotanopoulosDepartment of Surgery, Wake Forest University, Winston-Salem, North Carolina, USA.
Bradley A KrasnickDepartment of Surgery, Washington University School of Medicine, St Louis, Missouri, USA.ORCID http://orcid.org/0000-0003-2685-7259
Ryan C FieldsDepartment of Surgery, Washington University School of Medicine, St Louis, Missouri, USA.
Shervin V OskoueiDepartment of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
David K MonsonDepartment of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Nickolas B ReimerDepartment of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Shishir K MaithelDepartment of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Allan PickensDepartment of Surgery, Division of Cardiothoracic Surgery, Emory University, Atlanta, Georgia, USA.
Kenneth CardonaDepartment of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0002-8200-3269

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
J: NRSA Training CoreTL1TR002382 · NCATS · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Vasiliki Michopoulos · 2017 to 2026
$8.5M
NCATS NIH HHS TL1 TR002382NCATS NIH HHS UL1 TR002378
6 · The paper itself

Abstract

backgroundSurgical resection for sarcoma lung metastases has been associated with improved overall survival (OS).

methodsPatients who underwent curative-intent resection of sarcoma lung metastases (2000-2016) were identified from the US Sarcoma Collaborative. Patients with extrapulmonary metastatic disease or R2 resections of primary tumor or metastases were excluded. Primary endpoint was OS.

resultsThree hundred and fifty-two patients met inclusion criteria. Location of primary tumor was truncal/extremity in 85% (n = 270) and retroperitoneal in 15% (n = 49). Forty-nine percent (n = 171) of patients had solitary and 51% (n = 180) had multiple lung metastasis. Median OS was 49 months; 5-year OS 42%. Age ≥55 (HR 1.77), retroperitoneal primary (HR 1.67), R1 resection of primary (HR 1.72), and multiple (≥2) lung metastases (HR 1.77) were associated with decreased OS(all p < 0.05). Assigning one point for each factor, we developed a risk score from 0 to 4. Patients were then divided into two risk groups: low (0-1 factor) and high (2-4 factors). The low-risk group (n = 159) had significantly better 5-year OS compared to the high-risk group (n = 108) (51% vs. 16%, p < 0.001).

conclusionWe identified four characteristics that in aggregate portend a worse OS and created a novel prognostic risk score for patients with sarcoma lung metastases. Given that patients in the high-risk group have a projected OS of <20% at 5 years, this risk score, after external validation, will be an important tool to aid in preoperative counseling and consideration for multimodal therapy.

Indexed as

Patient SelectionPreoperative CareFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMetastasectomyMiddle AgedPrognosisRetrospective StudiesRisk FactorsSarcomaSurvival RateUnited Stateslung metastasismetastasectomyrisk scoresarcoma

Identifiers

PMID34374088
PMCPMC8595861

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.